Valuing a Cure: Evaluating Different Approaches to Determine a Value-Based Price for a Potential Cure
Principal Investigator: Steven D. Pearson, Institute for Clinical and Economic Review
Jan 01, 2019 - Nov 30, 2019
Summary of the Project:
Many drugs in the development pipeline offer the potential to cure patients but will almost certainly enter the market with very high price tags. This study will extend ICER's current value assessment framework to tackle difficult conceptual and methodological issues related to establishing fair, value-based initial prices for these drugs. The work will be applied to a real-world case study of an emerging potential cure and incorporated into an update of ICER's value assessment framework. Findings will also be shared with international technology assessment organizations.
Related Grantee Work
May 16, 2019
New Cost-Effectiveness Methods to Determine Value-Based Prices for Potential Cures: What Are the Options?
This article analyzes the challenges and presents several options to modify the conduct and presentation of cost-effectiveness analyses to ensure they provide policy-relevant assessments of the value of potential cures.Learn More
Author: S Pearson, D Ollendorf, R Chapman
January 16, 2019
This Gene Therapy Treatment for Blindness is the Most Expensive Drug in America
Reporting on the high cost of a successful gene therapy to treat blindness, this NBC News segment features Steven Pearson discussing how prices are set for innovative pharmaceutical products. With a NIHCM Foundation grant, Steven Pearson and Richard Chapman will build upon their existing body of work at ICER on value-based drug pricing.Learn More